ReviewOTO open
Biomarkers & Survival in Head and Neck Squamous Cell Carcinoma: A Systematic Review & Meta-Analysis.
Review in OTO open. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: EGFR, cyclin D1, and Bcl-2 are proteins involved in different stages of tumorigenesis which have all been associated with poor prognosis in head and neck squamous cell carcinoma (HNSCC). In this systematic review and meta-analysis, we aim to measure the association of each protein with survival in HNSCC. Data Sources: PubMed, Scopus, and Cochrane databases. Review Methods: A systematic review of EGFR, cyclin D1, and Bcl-2 was conducted to determine the association between overexpression and survival in HNSCC. A weighted random-effects meta-analysis then measured pooled rates of overall, disease-free, and disease-specific survival for each protein. Results: Overexpression of EGFR was associated with worse overall mortality (HR = 1.52, Conclusion: These findings support EGFR, cyclin D1, and Bcl-2 as biomarkers which portend worse prognosis in HNSCC. Further work will be needed to understand whether measurement of these proteins can be useful in tailoring treatment strategies, and whether they can be used as targets for novel therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.